Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 3, 2005, Pages 188-193

  Shaughnessy, Paul J ^a   Bachier, Carlos ^a   Grimley, Michael ^a   Freytes, Cesar O ^b,c   Callander, Natalie S ^b,c   Essell, James H ^d   Flomenberg, Neal ^e   Selby, George ^f   Lemaistre, C F ^a  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d JEWISH HOSPITAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Denileukin diftitox; Graft versus host disease; Steroid resistance

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; STEROID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; ARTICLE; ASTHENIA; CAPILLARY LEAK SYNDROME; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENZYME DEFECT; FEMALE; GRAM NEGATIVE SEPSIS; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; INFECTION; LEG EDEMA; LEG PAIN; LIVER TOXICITY; MALE; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; SCHOOL CHILD; THROMBOCYTOPENIA;

ACUTE DISEASE; CAPILLARY LEAK SYNDROME; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTERLEUKIN-2; LIVER DISEASES; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; STEROIDS;

EID: 14244265761     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.11.022     Document Type: Article

References (31)

1. P.J. Martin G. Schoch L. Fishter et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment Blood 76 1990 1464-1472
2. D. Weisdorf R. Haake B. Blazar et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome Blood 75 1990 1024-1030
3. P.J. Martin G.B. McDonald E.J. Sanders et al. Increasing frequent diagnosis of acute gastrointestinal graft versus host disease after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 10 2004 320-327
4. M.L. MacMillan D.J. Weisdorf J.E. Wagner et al. Response of 443 patients to steroids as primary therapy for acute graft versus host disease: Comparison of grading systems Biol Blood Marrow Transplant 8 2002 387-394
5. J.L. Ferrara J.H. Antin The pathophysiology of graft versus host disease In: E.D. Thomas K.G. Blume S.J. Forman, eds. Hematopoietic Cell Transplantation 1999 Blackwell Science Inc Malden, MA 19-27
6. T.A. Waldmann The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes Science 232 1986 727-732
7. F. Craig P. Banks Detection of the alpha and beta components of the interleukin-2 receptor using immunologic techniques [abstract] Mol Pathol 5 1992 188a
8. R.J. Robb W.C. Greene Internalization of interleukin-2 is mediated by the gamma chain of the high affinity interleukin-2 receptor J Exp Med 165 1987 1201-1206
9. T. Taniguchi Y. Minami The IL-2/IL-2 receptor system: A current overview Cell 73 1993 5-8
10. T.A. Waldmann The multichain interleukin-2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts JAMA 263 1990 272-274
11. 389IL-2) in lymphomas expressing the receptor for interleukin-2 Blood 91 1998 399-405
12. B.L. Kagan M. Finkelstein M. Colombini Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes Proc Natl Acad Sci U S A 78 1981 4950-4954
13. R. Fuchs S. Schmid I. Mellman A possible role for Na+, K+-ATPase in regulating ATP-dependent endosome acidification Proc Natl Acad Sci U S A 86 1998 539-543
14. P.A. Rowlings D. Przepiorka J.P. Klein et al. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade Br J Haematol 97 1997 855-864
15. National Institute of Health Common Terminology Criteria for Adverse Events 2003 Version 3.0. December 12
16. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1-10
17. P.J. Martin G. Schoch L. Fisher et al. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment Blood 77 1991 1821-1828
18. D. Przepiorka A. Kernan C. Ippoliti et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Blood 95 2000 83-89
19. A.I. Benito T. Fulong P.J. Martin et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease Transplantation 72 2001 1924-1929
20. P.J. Martin B.J. Nelson F.R. Appelbaum et al. Evaluation of a CD5-specific immunotoxin for the treatment of acute graft-versus-host disease after allogeneic marrow transplantation Blood 88 1996 824-830
21. P.A. Carpenter F.R. Appelbaum L. Corey et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid refractory acute graft-versus-host disease Blood 99 2002 2712-2719
22. D. Przepiorka G. Phillips V. Ratanatharathorn et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for the treatment of steroid resistant acute graft-versus-host disease Blood 92 1998 4066-4071
23. J. Deeg B. Blazar B. Bolwell et al. Treatment of steroid resistant acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL Blood 98 2001 2052-2058
24. D. Couriel R. Saliba K. Hicks et al. Tumor necrosis factor alpha blockade for the treatment of acute GVHD Blood 104 2004 649-654
25. V.T. Ho D. Zahrieh E. Hochberg et al. Safety and efficacy of denileukin diftitox in patients with steroid refractory acute graft versus host disease after allogeneic hematopoietic stem cell transplantation Blood 104 2004 1224-1226
26. E. Olsen M. Duvic A. Frankel et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376-388
27. M. Stanzani S. Martins R. Saliba et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk of graft-versus-host disease following HLA-identical stem cell transplantation in humans Blood 103 2004 1140-1146
28. M. Edinger P. Hoffmann J. Ermann et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation Nat Med 9 2003 1144-1150
29. P. Taylor C. Lees B. Blazar The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality Blood 99 2002 3493-3499
30. S. Lee D. Zahrieh E. Agura et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial Blood 104 2004 1559-1564
31. M. Saleh C.F. LeMaistre F. Kuzel et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides J Am Acad Dermatol 39 1998 63-73